Communication on the introduction of warnings and precautions for severe skin reactions with Xeloda® (capecitabine)

Roche would like to inform healthcare professionals of the introduction of warnings and precautions for severe skin reactions with Xeloda®(capecitabine). A recent review of the company safety database and literatures has identified reports of severe skin reactions such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), in some cases with a fatal outcome, during treatment with Xeloda®. The frequency of the severe skin reactions is estimated as very rare taking into account the exposure to Xeloda® as per April 2013. Healthcare professionals are advised to monitor and inform their patients on the potential causality of severe skin reactions to Xeloda® treatment. The package insert for Xeloda® will be updated to reflect the new safety information. Please refer to the Dear Healthcare Professional Letter for more details.

 
 
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.moh.gov.sg/hpp/, and follow the procedures below to access the MOH Alert system.

Step 1: On the top navigation ribbon of webpage, select 'For Healthcare Professionals' followed by 'Health Professionals Portal' and click on the choice of profession. User will be redirected to the specific HPP webpage for the selected profession.

Step 2: Click on the Restricted Content icon on the left panel of webpage and login via SingPass.

Step 3: Click on the MOH Alert icon under ‘Applications’ section

Step 4: Click on the Drug Alert tab to view the DHCPLs.